Randomized block design shows improved fasting blood glucose and efficacy in type 2 diabetic nephropathy patients with combined therapy.
This study analyzed the efficacy of the combination therapy of Veglitinide Tablets and Metformin Hydrochloride Tablets in treating type 2 diabetic nephropathy. A total of 80 patients admitted to our hospital between January 2024 and January 2025 were enrolled. Using a randomized block design, the patients were divided into two groups for prospective analysis. The control group received Metformin Hydrochloride Tablets, while the observation group received the combined therapy of Veglitinide Tablets and Metformin Hydrochloride Tablets. The improvements in blood glucose levels and renal function were compared between the groups. Post-treatment analysis showed that the observation group exhibited lower fasting blood glucose and 2-hour postprandial glucose levels (P<0.05), with significantly reduced serum creatinine and blood urea nitrogen levels (P<0.05). The combined therapy demonstrated significant therapeutic effects in type 2 diabetic nephropathy patients, effectively regulating both blood glucose and renal function.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: